Induction of group II-like phospholipase A2 by lipopolysaccharide in the liver of BCG-primed rat.
The specific activity of phospholipase A2 (PLA2) in the liver homogenate was elevated 1.7-fold in bacillus Calmette-Guerin (BCG)-treated rats, 1.6-fold in lipopolysaccharide (LPS)-treated rats, and 2.4-fold in BCG-infected rats treated with LPS, compared with that of control rats. These increased activities were almost completely inhibited by the antibody directed against rat splenic group II PLA2 (PLA2M) but not by anti-pancreatic PLA2 antibody. The results of immunoblot analysis confirmed that the PLA2 immunochemically related to the group II enzyme was induced by treatment with BCG and/or LPS. The anti-PLA2M antibody-inhibitable PLA2 activity per a single cell was elevated not only in nonparenchymal cell fraction but also in hepatocyte fraction, as in the case of whole liver. On the contrary, the PLA2 concentration and its specific activity did not change by the same treatment both in spleen homogenate and in isolated spleen cell fractions although a 3-fold increase in spleen mass occurred by BCG treatment. These results suggested that a tissue-specific mechanism of the PLA2 induction by these inflammatory mediators may operate in liver.
Inada
M
M
Second Department of Internal Medicine, Osaka University Medical School, Japan.
Tojo
H
H
Kawata
S
S
Tarui
S
S
Okamoto
M
M
D000818:Animals; D004790:Enzyme Induction; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000276:immunology; D008297:Male; D009163:Mycobacterium bovis; D010741:Phospholipases A / Q000096:biosynthesis*; D054467:Phospholipases A2; D051381:Rats; D011919:Rats, Inbred Strains; D012016:Reference Values; D013154:Spleen / Q000187:drug effects / Q000201:enzymology / Q000276:immunology
D008070:Lipopolysaccharides; D010741:Phospholipases A; D054467:Phospholipases A2